drugset / Trial / NCT07107802
Phase 1 Single Ascending Dose Study With ATX101
RandomizedSequentialTriple-blindTreatment
Summary
The main objective of this study is to assess the safety and tolerability of intravenously administered ATX101 in healthy adults following single ascending doses of ATX101. The pharmacokinetic profile of ATX101 and its metabolites will also be investigated.
Timeline
- Start
- 2025-07-19
- Primary completion
- 2025-10-24
- Completion
- 2025-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ATX-101 | Peptide | — | Intravenous |
Indications
No indication recorded.